GlassScriptPhysician profile
Jeffrey P Rowand
NPI 1245523034
$9,632.70
in general payments reported to CMS, 2019-2025
54 companies · $1,474 in 2025
The $1,474 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $984 · 2020: $1,021 · 2021: $1,303 · 2022: $1,659 · 2023: $1,474 · 2024: $1,717 · 2025: $1,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,664.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,032.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $991.32 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $929.55 | 2019-2025 | |
| Abbvie INC. | $901.91 | 2020-2025 | Vraylar, Linzess, Qulipta |
| Astrazeneca Pharmaceuticals LP | $858.65 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $682.89 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $441.06 | 2019-2024 | Xarelto |
| Amgen INC. | $306.30 | 2019-2024 | Evenity, Prolia, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.32 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $263.44 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $244.44 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $198.00 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.88 | 2020-2024 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $170.77 | 2024-2025 | Voquezna |
| Abbott Laboratories | $166.35 | 2021-2025 | Freestyle Libre 3 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Rowand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.